A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.
Following its latest funding round, Rosa Biotech has announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective screening of a range of diseases with high accuracy at an early stage.